Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Slides:

Advertisements

Similar presentations

Elizabeth A. David, MD, David T

Advertisements

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Thomas J. Birdas, MD, Richard P. M

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

Chun Chieh Lin, PhD, MBA, Matthew P

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Joshua E. Rosen, BASc, Hari B

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Lars P. Riber, MD, PhD, Thomas D. Christensen,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

B. Zane Atkins, MD, Rebecca P. Petersen, MD, MS, Mani A

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis Naoto Morimoto,

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Operative Results and Outcomes in Children With Shone's Anomaly

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Andrea S. Wolf, MD, MPH, Scott J

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Kenji Suzuki, MD, Hisao.

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Pulmonary Resection in the Treatment of Multidrug-Resistant Tuberculosis: A Retrospective Study of 56 Cases Haifeng Wang, MM, Hongsheng Lin, MM, Gening.

Lung Cancer Surgery in Patients With Liver Cirrhosis

Total Arterial Revascularization: A Superior Strategy for Diabetic Patients Who Require Coronary Surgery James Tatoulis, MD, FRACS, Rochelle Wynne, PhD,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Expression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung Cancer Zhenfa Zhang, MD, Jianqun Ma, MD, Ni Li, PhD, Nan Sun, MD,

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant,

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD,

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Prognostic Analysis for Survival After Resections of Localized Primary Cardiac Sarcomas: A Single-Institution Experience Hua Li, MD, PhD, Deming Xu,

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

Modern Outcome and Risk Analysis of Surgically Resected Occult N2 Non-Small Cell Lung Cancer Hyun Jin Cho, MD, Sung Ryong Kim, MD, Hyeong Ryul Kim, MD,

Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Visceral Pleural Invasion Is Not a Significant Prognostic Factor in Patients With a Part- Solid Lung Cancer Aritoshi Hattori, MD, Kenji Suzuki, MD, Takeshi.

Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I.

Bryan M. Burt, MD, Santiago Ocejo, MD, Carlos M

Presentation transcript:

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue Li, MD, Zhen-fa Zhang, MD, PhD, Jian You, MD, PhD, Chang-li Wang, MD, PhD The Annals of Thoracic Surgery Volume 96, Issue 6, Pages 1943-1951 (December 2013) DOI: 10.1016/j.athoracsur.2013.07.089 Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Typical photomicrographs show expression of osteopontin (OPN) and CD44 immunohistochemistry in tissue microarray. Diaminobenzidine solution is the stain used in all images. (A) OPN+ (original magnification × 40); (B) OPN+ (original magnification ×100); (C) OPN– (original magnification ×40); (D) OPN– (original magnification ×100; (E) CD44v6+ (original magnification ×40); (F) CD44v6+ (original magnification ×100); (G) CD44v6– (original magnification ×40); and (H) CD44v6– (original magnification ×100). The Annals of Thoracic Surgery 2013 96, 1943-1951DOI: (10.1016/j.athoracsur.2013.07.089) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Prognostic significance assessed using Kaplan-Meier survival estimates and log-rank tests. Comparisons are shown of overall survival and disease-free survival (DFS) by (A and B) osteopontin (OPN) and (C and D) CD44v6. The Annals of Thoracic Surgery 2013 96, 1943-1951DOI: (10.1016/j.athoracsur.2013.07.089) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Kaplan-Meier analysis of (A) overall survival and (B) disease-free survival for combined osteopontin (OPN) and CD44v6. The Annals of Thoracic Surgery 2013 96, 1943-1951DOI: (10.1016/j.athoracsur.2013.07.089) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Kaplan-Meier analysis shows (A) overall survival and (B) disease-free survival for combined osteopontin (OPN) and CD44v6 in non-small cell lung cancer patients at stage I. The Annals of Thoracic Surgery 2013 96, 1943-1951DOI: (10.1016/j.athoracsur.2013.07.089) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions